Sort
15,440 grants matching “organoids”
Cancer Pharmacologist and HTS Scientist
$218,965Joshua A. Bauer · Vanderbilt University · R50 · FY2022 · CA
Cancer Pharmacologist and HTS Scientist
$218,965Joshua A. Bauer · Vanderbilt University · R50 · FY2024 · CA
Cancer Pharmacologist and HTS Scientist
$218,965Joshua A. Bauer · Vanderbilt University · R50 · FY2025 · CA
Red-light driven targeted degradation of cancer proteins
$218,886Neel H Shah · Columbia Univ New York Morningside · R61 · FY2025 · CA
The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer
$218,790Stefanie Galban · University Of Michigan At Ann Arbor · R21 · FY2024 · CA
Targeting cancer stem-like cells and inflammation for colon cancer chemoprevention
$218,790Grace Y. Chen · University Of Michigan At Ann Arbor · R21 · FY2023 · CA
Development of a clinically relevant mouse model of lung cancer cachexia to study pathoetiology and therapeutic strategies
$218,790Michael J Toth · University Of Vermont & St Agric College · R21 · FY2023 · CA
Targeting the metabolic vulnerabilities of patient-derived drug resistant tumors
$218,790Maria L Avantaggiati · Georgetown University · R21 · FY2021 · CA
Developing a novel approach to the nonhuman primate placental organoid model
$218,750Victoria Hj Roberts · Oregon Health & Science University · R21 · FY2022 · HD
Biorepository Core B
$218,706Claudio Fiocchi · Case Western Reserve University · P30 · FY2020 · DK
(PQ11) Dietary strategies to enhance FOLFOX cancer therapies
$218,700Daniel W Rosenberg · University Of Connecticut Sch Of Med/Dnt · R21 · FY2019 · CA
Microbiome-derived regulators of therapy-resistant colorectal tumors
$218,550Timothy J. Griffin · University Of Minnesota · R21 · FY2022 · CA
Application of mucus modulating multipurpose trypsin nanoparticles to overcome the mucus barrier and deliver mitochondria-targeted anticancer drugs in mucinous carcinoma peritonei
$218,538Mohammad Haroon Asif Choudry · University Of Pittsburgh At Pittsburgh · R21 · FY2023 · CA
Ex vivo generation of tumor-reactive T cells for adoptive cell transfer using an immune enhanced, patient derived tumor organoid-on-a-chip (iTOC)
$218,513Aleksander Skardal · Ohio State University · R21 · FY2022 · CA
Investigating Pathophysiology of Glioma Stem Cells in 3D Bioprinted Vascularized Glioblastoma Model
$218,462Irtisha Singh · Texas A&M University Health Science Ctr · R21 · FY2022 · NS
Implementation of a vaginal/rectal HIV transmission to model to evaluate microbic
$218,381J. Victor Garcia-Martinez · Ut Southwestern Medical Center · R21 · FY2007 · AI
A multiwell plate format microfluidic immobilization chip for high-content imaging of whole animals
$218,367Evan Hegarty · Vivoverse, Llc · R43 · FY2018 · MH
TMPRSS2-ERG chromosomal translocations and prostate cancer
$218,349Kathleen Kelly · Division Of Basic Sciences - Nci · ZIA · FY2018 · CA
Hybrid-nanomaterials for non-genetic optical stimulation of excitable cells
$218,312Tzahi Cohen-Karni · Carnegie-Mellon University · R21 · FY2020 · EB
Tissue Modeling and Drug Discovery Core
$218,134Hernan Alcides Flores-Rozas · Florida Agricultural And Mechanical Univ · U54 · FY2025 · CA
Organoid modeling of pre-metastatic niche formation in the liver by primary colorectal tumor secreted factors
$218,068Aleksander Skardal · Ohio State University · R21 · FY2022 · CA
Research Project 3: Optimizing DNA damage repair-targeted combination therapy
$218,062Funda Meric-Bernstam · University Of Tx Md Anderson Can Ctr · U54 · FY2021 · CA
Project 2: Building Combinatorial Therapies against KRAS-mutant Colorectal and Pancreatic Cancer
$218,060Scott Kopetz · University Of Tx Md Anderson Can Ctr · U54 · FY2021 · CA
Core C: Sphingolipid Cancer Animal Pathology Core
$218,041Ashley Jones Snider · State University New York Stony Brook · P01 · FY2020 · CA
Core C: Sphingolipid Cancer Animal Pathology Core
$218,041Ashley Jones Snider · State University New York Stony Brook · P01 · FY2019 · CA